P Klener

Summary

Affiliation: Charles University
Country: Czech Republic

Publications

  1. ncbi request reprint [ABL1, SRC and other non-receptor protein tyrosine kinases as new targets for specific anticancer therapy]
    P Klener
    Interní klinika, klinika hematologie VFN a 1 LF UK v Praze
    Klin Onkol 23:203-9. 2010
  2. ncbi request reprint [Epigenetic cancer drugs and their role in anticancer therapy]
    P Klener
    Interní klinika 1 lékařské fakulty UK a VFN v Praze
    Vnitr Lek 59:463-5. 2013
  3. ncbi request reprint [Targeted therapeutics and their role in the treatment of internal diseases]
    P Klener
    Interní Klinika 1 Lékarské Fakulty UK a VFN a UHKT Praha
    Vnitr Lek 59:5-12. 2013
  4. ncbi request reprint [Angiogenesis as part of the tumor "ecosystem" and possibilities to influence it]
    P Klener
    1 interní hemato onkologická klinika 1 LF a VFN a UHKT, Praha
    Klin Onkol 23:14-20. 2010
  5. ncbi request reprint [Some new findings in the pathogenesis of myeloproliferative disorders and new insight into more effective treatment]
    P Klener
    I interni klinika 1 LF UK a VFN a UHKT, Praha
    Cas Lek Cesk 145:4-8. 2006
  6. ncbi request reprint [Current and perspective treatment of chronic lymphocytic leukemia]
    P Klener
    I interni klinika 1 LF UK a VFN a UHKT, Praha
    Cas Lek Cesk 144:75-80. 2005
  7. ncbi request reprint [Imatinib--a new perspective in the treatment of tumors]
    P Klener
    I interni klinika 1 LF UK a VFN a UHKT, Praha
    Cas Lek Cesk 143:579-80, 582-3. 2004
  8. ncbi request reprint [Perspectives in antineoplasm chemotherapy]
    P Klener
    I interní klinika 1 LF UK a VFN, Praha
    Cas Lek Cesk 140:605-10. 2001
  9. ncbi request reprint [Bortezomib (Velcade) in relapsed/refractory multiple myeloma--the first experience in the Czech Republic]
    I Spicka
    I interní klinika 1, LF UK a VFN, Praha
    Cas Lek Cesk 144:636, 638-40. 2005
  10. ncbi request reprint The role of apoptosis in cancer development and treatment: focusing on the development and treatment of hematologic malignancies
    J Zivny
    the Institute of Pathological Physiology, Charles University in Prague, First Faculty of Medicine, U nemocnice 5, 128 53 Prague 2, Czech Republic
    Curr Pharm Des 16:11-33. 2010

Collaborators

Detail Information

Publications13

  1. ncbi request reprint [ABL1, SRC and other non-receptor protein tyrosine kinases as new targets for specific anticancer therapy]
    P Klener
    Interní klinika, klinika hematologie VFN a 1 LF UK v Praze
    Klin Onkol 23:203-9. 2010
    ..New generation tyrosine kinase inhibitors (e.g. dasatinib) with extended activity against SRC and EPH kinases belong to promising anti-cancer agents with documented preclinical activity in several solid tumours (e.g. prostate cancer)...
  2. ncbi request reprint [Epigenetic cancer drugs and their role in anticancer therapy]
    P Klener
    Interní klinika 1 lékařské fakulty UK a VFN v Praze
    Vnitr Lek 59:463-5. 2013
    ....
  3. ncbi request reprint [Targeted therapeutics and their role in the treatment of internal diseases]
    P Klener
    Interní Klinika 1 Lékarské Fakulty UK a VFN a UHKT Praha
    Vnitr Lek 59:5-12. 2013
    ..Classification of targeted drugs and their use in the clinical practice is shortly reviewed...
  4. ncbi request reprint [Angiogenesis as part of the tumor "ecosystem" and possibilities to influence it]
    P Klener
    1 interní hemato onkologická klinika 1 LF a VFN a UHKT, Praha
    Klin Onkol 23:14-20. 2010
    ....
  5. ncbi request reprint [Some new findings in the pathogenesis of myeloproliferative disorders and new insight into more effective treatment]
    P Klener
    I interni klinika 1 LF UK a VFN a UHKT, Praha
    Cas Lek Cesk 145:4-8. 2006
    ..More detailed information is given on some novel drugs which are currently in clinical trials...
  6. ncbi request reprint [Current and perspective treatment of chronic lymphocytic leukemia]
    P Klener
    I interni klinika 1 LF UK a VFN a UHKT, Praha
    Cas Lek Cesk 144:75-80. 2005
    ..New drugs can influence intracellular events such as induction of apoptosis or inhibition of the transduction cascade. Review summarises treatment alternatives and presents an algorithm for their clinical application...
  7. ncbi request reprint [Imatinib--a new perspective in the treatment of tumors]
    P Klener
    I interni klinika 1 LF UK a VFN a UHKT, Praha
    Cas Lek Cesk 143:579-80, 582-3. 2004
    ..Possible combination of imatinib with conventional chemotherapeutic drugs and other key signal transduction inhibitors are mentioned...
  8. ncbi request reprint [Perspectives in antineoplasm chemotherapy]
    P Klener
    I interní klinika 1 LF UK a VFN, Praha
    Cas Lek Cesk 140:605-10. 2001
    ..Increased understanding in the mechanisms driving cellular proliferation emerges novel therapeutics that are more specific and less toxic than classical chemotherapy...
  9. ncbi request reprint [Bortezomib (Velcade) in relapsed/refractory multiple myeloma--the first experience in the Czech Republic]
    I Spicka
    I interní klinika 1, LF UK a VFN, Praha
    Cas Lek Cesk 144:636, 638-40. 2005
    ..Proteasome inhibitors are the example of this new approach and bortezomib is the first agent in this class to enter clinical trials...
  10. ncbi request reprint The role of apoptosis in cancer development and treatment: focusing on the development and treatment of hematologic malignancies
    J Zivny
    the Institute of Pathological Physiology, Charles University in Prague, First Faculty of Medicine, U nemocnice 5, 128 53 Prague 2, Czech Republic
    Curr Pharm Des 16:11-33. 2010
    ....
  11. ncbi request reprint [Proteasome inhibitors--new option in the treatment of tumor diseases]
    I Spicka
    I interní klinika 1 LF UK a VFN, Praha
    Cas Lek Cesk 143:701-4. 2004
    ..Proteasome inhibitors are the example of this new approach and bortezomib is the first agent in this class, which enters clinical trials. We summarize theoretical background and the first clinical experiences with this drug...
  12. ncbi request reprint [Cefepime as an empiric treatment of febrile neutropenia in patients after high dose therapy and autologous stem cell transplantation]
    E Zikesoá
    I interní klinika 1 LF UK a VFN, Praha
    Cas Lek Cesk 145:383-6, 388-9. 2006
    ..This retrospective study was initiated to assess efficacy and safety of cefepime as an empiric therapy of febrile neutropenia following high dose therapy and autologous stem cell transplantation...
  13. ncbi request reprint [Long-term culture of plasma cells from patients with myeloma and establishment of a permanent cell line]
    P Stockbauer
    Ustav hematologie a krevni transfuze, U Nemocnice 1, 128 20 Praha 2, Czech Republic
    Sb Lek 103:371-7. 2002
    ..In three cases permanent B-lymphoblastoid cell lines were established (UHKT-55, UHKT-56 a UHKT-57) but secondary immortalization by Epstein-Barr virus was suggested...